 | This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these template messages)
|
 | |
| Company type | Public |
|---|---|
| SSE: 603259 | |
| Industry | Contract Research Organizations Pharmaceutical Biopharmaceutical Medical Devices |
| Founded | 2000 |
| Headquarters | Shanghai, China |
Key people | Ge Li |
| Website | www |
WuXi AppTec (WuXi is pronounced as Wu-shee) is a global pharmaceutical, biopharmaceutical, and medical device company.
WuXi PharmaTech was founded in December 2000 in Shanghai by organic chemist Ge Li. [1] [2]
The company opened chemistry facilities in Tianjin in 2007. In 2008, WuXi PharmaTech acquired AppTec Laboratory Services Inc., a US-based company founded in 2001 with expertise in medical-device and biologics testing and with facilities in St. Paul, MN; Philadelphia, PA; and Atlanta, GA. In the same year the company was renamed WuXi AppTec. [3] [4] WuXi AppTec opened a toxicology facility in Suzhou in 2009. [5]
WuXi AppTec's subsidiary, WuXi STA, opened a large-scale manufacturing facility in Jinshan in 2010. The company began a biologics discovery, development, and manufacturing operation in Shanghai and Wuxi City in 2011. At the same year, WuXi AppTec acquired MedKey, a China-based clinical research company, [6] and Abgent, a San Diego company and one of the world's largest manufacturers of antibodies for biological research and drug discovery. [7] In 2012, WuXi AppTec opened a chemistry facility in Wuhan and a GMP biologics drug-substance facility in Wuxi City. That year WuXi AppTec also entered into a joint venture with MedImmune, the biologics arm of AstraZeneca, to co-develop MEDI5117, an anti-IL6 antibody for rheumatoid arthritis for the Chinese market. [8] In 2013, WuXi AppTec formed a joint venture with the global clinical contract research organization PRA International (now called PRA Health Sciences) to build a clinical research business in China. [9]
In 2014, WuXi AppTec opened a new biologics biosafety testing facility in Suzhou. In the same year, WuXi AppTec acquired XenoBiotic Laboratories, Inc. (XBL), a contract research organization with 27 years of operation that provides bioanalytical, drug metabolism, and pharmacokinetic services to the pharmaceutical, animal health, and agrochemical industries. [10]
In 2015, the company launched the subsidiary WuXi NextCODE following the acquisition of NextCODE Health, a bioinformatics startup company which emerged from the Icelandic firm deCODE genetics in 2013. [11]
In 2015, WuXi AppTec completed its merger with WuXi Merger Limited, a wholly owned subsidiary of New WuXi Life Science Limited. As a result of the merger, New WuXi Life Science Limited acquired the company in a cash transaction valued at approximately US$3.3 billion. [12] In 2016, WuXi STA opened a new campus in Changzhou [13] and operations in San Diego. In the same year, WuXi AppTec acquired Crelux GmbH, a structure-based drug discovery provider based in Munich, Germany. [14] In 2017, WuXi AppTec acquired HD Biosciences (HDB), a biology focused preclinical drug discovery contract research organization (CRO). [15]
In January 2024, WuXi AppTec's share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. [16] [17] [18] The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army (PLA) as a part of the Chinese Communist Party (CCP)'s military-civil fusion strategy. [19] Members of the United States House Select Committee on Strategic Competition between the United States and the Chinese Communist Party subsequently called for sanctions against WuXi AppTec. [20] WuXi AppTec denied any affiliation with the CCP and PLA and launched a lobbying campaign in the US in response. [21] According to the Federal Bureau of Investigation, United States Department of State, and Director of National Intelligence, WuXi AppTec transferred US intellectual property to the PLA without consent. [22]
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.
AstraZeneca plc (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine.
Labcorp Drug Development is a contract research organization headquartered in Burlington, North Carolina, providing nonclinical, preclinical, clinical and commercialization services to pharmaceutical and biotechnology industries. Formerly called Covance, the company is part of Labcorp, which employs more than 70,000 people worldwide.
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000 and included hundreds of scientists, making Amgen the largest employer in Ventura County. As of 2022, Amgen has approximately 24,000 staff in total.
Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products, outsourcing services, and animals for research and development in the pharmaceutical industry and offers support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.
Thermo Fisher Scientific Inc. is an American supplier of analytical instruments, life sciences solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).
Abgent is a global biotechnology company based in San Diego, California, US with offices in Maidenhead, UK and Suzhou, China and distributors around the world. Abgent develops antibodies and related agents to study proteins involved in cellular function and disease. Abgent's antibodies target key areas of research including autophagy, neuroscience, cancer, stem cells and more. Abgent was acquired in 2011 by WuXi AppTec, a global pharmaceutical, biopharmaceutical, and medical device outsourcing company with operations in China and the United States.
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.
Martin Shkreli is an American financial criminal and businessman. Shkreli is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, the co-founder and former CEO of pharmaceutical firms Retrophin and Turing Pharmaceuticals, and the former CEO of start-up software company Gödel Systems, which he founded in August 2016.
Dotmatics is an R&D scientific software company used by scientists in the R&D process that help them be more efficient in their efforts to innovate. Founded in 2005, the company's primary office is in Boston with 14 offices around the globe. In March 2021, Insightful Science acquired Dotmatics. In April 2022, the two companies consolidated under the Dotmatics brand with Insightful Science CEO Thomas Swalla leading the new Dotmatics. Dotmatics' software is used by 2 million scientists and researchers and 10,000 customers.
Catalent, Inc. is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.
Insilico Medicine is a biotechnology company based in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong Kong, and in New York, at The Cure by Deerfield. The company combines genomics, big data analysis, and deep learning for in silico drug discovery.
WuXi Biologics is a global Contract Research Development and Manufacturing Organization (CRDMO) that provides open-access, integrated technology platforms for biologics drug development.
ICON plc is an Irish headquartered Nasdaq listed multinational healthcare intelligence and clinical research organisation that provides consulting, clinical development and commercialisation services for the pharmaceutical industry. As of June 2023, ICON had approximately 41,160 employees in 108 locations spread across 53 countries.
GenScript Biotech, fully known as GenScript Biotech Corporation, usually referred to as simply GenScript, is a New Jersey-based biotech company. It was co-founded in 2002 in New Jersey by Fangliang Zhang, Ye Wang, and Luquan Wang. The company mainly provides life science research application instruments and services. It was listed on the Hong Kong Stock Exchange in 2015. The current rotating CEO of the firm is Shao Weihui, and its main subsidiaries include Legend Biotech, Probio Technology, and Bestzyme.
Ge Li is a Chinese American entrepreneur and philanthropist. He is the founder and chairman of WuXi AppTec, a contract pharmaceutical research firm.
